{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:35:48Z","timestamp":1789684548463,"version":"4.0.1"},"reference-count":69,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.nrleng.2025.07.004","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T07:04:24Z","timestamp":1752822264000},"page":"700-712","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Blood-based biomarkers for Alzheimer's disease: positioning document and usage recommendations from the Behavioral Neurology and Dementia Study Group of the Spanish Society of Neurology"],"prefix":"10.1016","volume":"40","author":[{"given":"M.","family":"Su\u00e1rez-Calvet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Abdelnour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Alcolea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mendi\u00f3roz-Iriarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Balasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Morenas-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Puig-Pijoan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"S\u00e1nchez-Juan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Villarejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"S\u00e1nchez-Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nrleng.2025.07.004_bib0005","doi-asserted-by":"crossref","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","article-title":"High-precision plasma \u03b2-amyloid 42\/40 predicts current and future brain amyloidosis","volume":"93","author":"Schindler","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0010","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","article-title":"Plasma P-tau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia","volume":"26","author":"Janelidze","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0015","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature25456","article-title":"High performance plasma amyloid-\u03b2 biomarkers for Alzheimer\u2019s disease","volume":"554","author":"Nakamura","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0020","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","article-title":"Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology","volume":"81","author":"Ashton","year":"2024","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0025","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","article-title":"Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts","volume":"19","author":"Karikari","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0030","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","article-title":"Diagnostic value of plasma phosphorylated tau181 in Alzheimer\u2019s disease and frontotemporal lobar degeneration","volume":"26","author":"Thijssen","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0035","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/alz.12841","article-title":"Plasma and CSF biomarkers in a memory clinic: head-to-head comparison of phosphorylated tau immunoassays","volume":"19","author":"Ashton","year":"2023","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0040","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders","volume":"324","author":"Palmqvist","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0045","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","article-title":"Plasma p-tau231: a new biomarker for incipient Alzheimer\u2019s disease pathology","volume":"141","author":"Ashton","year":"2021","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0050","first-page":"1797","article-title":"Plasma p-tau231 and p-tau217 as state markers of amyloid-\u03b2 pathology in preclinical Alzheimer\u2019s disease","volume":"28","author":"Mil\u00e0-Alom\u00e0","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0055","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1001\/jamaneurol.2021.3671","article-title":"Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum","volume":"78","author":"Benedet","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0060","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1038\/s41467-021-23620-z","article-title":"A multicentre validation study of the diagnostic value of plasma neurofilament light","volume":"12","author":"Ashton","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0065","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","article-title":"Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019","volume":"7","author":"Nichols","year":"2022","journal-title":"Lancet Public Heal"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0070","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimer\u2019s Dement"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0075","series-title":"World Alzheimer Report 2021: journey through the diagnosis of dementia","author":"Gauthier","year":"2021"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0080","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0085","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0090","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0095","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209402","article-title":"Proportion of community-dwelling individuals older than 70 years eligible for lecanemab initiation","volume":"102","author":"Dittrich","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0105","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/s41591-024-02869-z","article-title":"Highly accurate blood test for Alzheimer\u2019s disease is similar or superior to clinical cerebrospinal fluid tests","volume":"30","author":"Barth\u00e9lemy","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0110","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jalz.2017.06.2266","article-title":"Amyloid \u03b2 concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis","volume":"13","author":"Ovod","year":"2017","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0115","first-page":"434","article-title":"Population-based blood screening for preclinical Alzheimer\u2019s disease in a British birth cohort at age 70","volume":"144","author":"Keshavan","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0120","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1001\/jamaneurol.2019.1632","article-title":"Performance of fully automated plasma assays as screening tests for Alzheimer disease\u2013related \u03b2-amyloid status","volume":"76","author":"Palmqvist","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0125","doi-asserted-by":"crossref","DOI":"10.1038\/srep26801","article-title":"Plasma \u03b2-amyloid in Alzheimer\u2019s disease and vascular disease","volume":"6","author":"Janelidze","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0130","doi-asserted-by":"crossref","first-page":"e12921","DOI":"10.15252\/emmm.202012921","article-title":"Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer\u2019s continuum when only subtle changes in A\u03b2 pathology are detected","volume":"12","author":"Su\u00e1rez-Calvet","year":"2020","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0135","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1474-4422(21)00214-3","article-title":"Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer\u2019s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study","volume":"20","author":"Thijssen","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0140","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S1474-4422(21)00129-0","article-title":"Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study","volume":"20","author":"Carmona-Iragui","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0145","doi-asserted-by":"crossref","DOI":"10.1038\/s41398-020-01137-1","article-title":"Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer\u2019 s disease","volume":"11","author":"Chatterjee","year":"2021","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0150","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1093\/brain\/awab223","article-title":"Plasma GFAP is an early marker of amyloid-\u03b2 but not tau pathology in Alzheimer\u2019s disease","volume":"144","author":"Pereira","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0155","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1016\/S2666-7568(20)30061-1","article-title":"Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study","volume":"2","author":"Verberk","year":"2021","journal-title":"Lancet Heal Longev"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0160","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1001\/jamaneurol.2021.3180","article-title":"Head-to-head comparison of 8 plasma amyloid-\u03b2 42\/40 assays in Alzheimer disease","volume":"78","author":"Janelidze","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0165","first-page":"e688","article-title":"Validation of plasma amyloid-\u03b2 42\/40 for detecting Alzheimer disease amyloid plaques","volume":"98","author":"Li","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0170","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1515\/cclm-2021-0651","article-title":"Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid","volume":"60","author":"Gobom","year":"2021","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-021-00942-0","article-title":"The accuracy and robustness of plasma biomarker models for amyloid PET positivity","volume":"14","author":"Benedet","year":"2022","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0180","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jamaneurol.2023.4719","article-title":"Effect of neprilysin inhibition on Alzheimer disease plasma biomarkers: a secondary analysis of a randomized clinical trial","volume":"81","author":"Brum","year":"2024","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0185","article-title":"Effects of pre\u2010analytical procedures on blood biomarkers for Alzheimer\u2019s pathophysiology, glial activation, and neurodegeneration","volume":"13","author":"Ashton","year":"2021","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0190","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1002\/alz.13014","article-title":"Blood-brain barrier integrity impacts the use of plasma amyloid-\u03b2 as a proxy of brain amyloid-\u03b2 pathology","volume":"19","author":"Bellaver","year":"2023","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0195","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/s41582-022-00665-2","article-title":"Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility","volume":"18","author":"Karikari","year":"2022","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0200","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00401-020-02195-x","article-title":"Plasma p-tau181 accurately predicts Alzheimer\u2019s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline","volume":"140","author":"Lantero Rodriguez","year":"2020","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0205","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1093\/brain\/awac333","article-title":"Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer\u2019s disease","volume":"146","author":"Janelidze","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0210","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1038\/s41591-022-02074-w","article-title":"Differential roles of A\u03b242\/40, p-tau231 and p-tau217 for Alzheimer\u2019s trial selection and disease monitoring","volume":"28","author":"Ashton","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0215","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1001\/jamaneurol.2022.3392","article-title":"Association of donanemab treatment with exploratory plasma biomarkers in early symptomatic Alzheimer disease: a secondary analysis of the TRAILBLAZER-ALZ randomized clinical trial","volume":"79","author":"Pontecorvo","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0220","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.3233\/JAD-231479","article-title":"Plasma phosphorylated tau 231 increases at one-year intervals in cognitively unimpaired subjects","volume":"98","author":"Mart\u00ednez-Dubarbie","year":"2024","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0225","doi-asserted-by":"crossref","first-page":"5343","DOI":"10.1002\/alz.13119","article-title":"Plasma and CSF concentrations of N-terminal tau fragments associate with in vivo neurofibrillary tangle burden","volume":"19","author":"Lantero-Rodriguez","year":"2023","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0230","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/s43587-023-00405-1","article-title":"Mass spectrometric simultaneous quantification of tau species in plasma shows differential associations with amyloid and tau pathologies","volume":"3","author":"Montoliu-Gaya","year":"2023","journal-title":"Nat Aging"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0235","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1038\/s41467-024-46876-7","article-title":"Plasma p-tau212 antemortem diagnostic performance and prediction of autopsy verification of Alzheimer\u2019s disease neuropathology","volume":"15","author":"Kac","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0240","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1093\/brain\/awac407","article-title":"Brain-derived tau: a novel blood-based biomarker for Alzheimer\u2019s disease-type neurodegeneration","volume":"146","author":"Gonzalez-Ortiz","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0245","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1136\/jnnp-2021-326603","article-title":"Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias","volume":"92","author":"Alcolea","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0250","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1007\/s12035-020-02035-9","article-title":"Different clinical contexts of use of blood neurofilament light chain protein in the spectrum of neurodegenerative diseases","volume":"57","author":"Palermo","year":"2020","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0255","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.jagp.2024.03.008","article-title":"Clinical accuracy of serum neurofilament light to differentiate frontotemporal dementia from primary psychiatric disorders is age-dependent","volume":"32","author":"Light","year":"2024","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0260","doi-asserted-by":"crossref","first-page":"fcac174","DOI":"10.1093\/braincomms\/fcac174","article-title":"Establishment of reference values for plasma neurofilament light based on healthy individuals aged 5-90 years","volume":"4","author":"Simren","year":"2022","journal-title":"Brain Commun"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0265","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3233\/JAD-2009-1075","article-title":"Glial fibrillary acidic protein and protein S-100B: different concentration pattern of glial proteins in cerebrospinal fluid of patients with Alzheimer\u2019s disease and Creutzfeldt-Jakob disease","volume":"17","author":"Jesse","year":"2009","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0270","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/jnc.13399","article-title":"Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer\u2019s disease, dementia with Lewy bodies, and frontotemporal lobar degeneration","volume":"136","author":"Ishiki","year":"2016","journal-title":"J Neurochem"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0275","first-page":"16","article-title":"Serum GFAP levels correlate with astrocyte reactivity, post-mortem brain atrophy and neurofibrillary tangles","volume":"139","author":"S\u00e1nchez-Juan","year":"2024","journal-title":"Brain"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0280","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1002\/alz.12510","article-title":"Characterization of pre\u2010analytical sample handling effects on a panel of Alzheimer\u2019s disease\u2013related blood\u2010based biomarkers: results from the Standardization of Alzheimer\u2019s Blood Biomarkers (SABB) working group","volume":"18","author":"Verberk","year":"2021","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0285","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13024-021-00430-x","article-title":"Moving fluid biomarkers for Alzheimer\u2019s disease from research tools to routine clinical diagnostics","volume":"16","author":"Zetterberg","year":"2021","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0290","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1002\/alz.12756","article-title":"The Alzheimer\u2019s Association appropriate use recommendations for blood biomarkers in Alzheimer\u2019s disease","volume":"18","author":"Hansson","year":"2022","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0295","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jalz.2013.01.010","article-title":"CSF biomarker variability in the Alzheimer\u2019s Association quality control program","volume":"9","author":"Mattsson","year":"2013","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0300","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1212\/WNL.0000000000207193","article-title":"Blood biomarkers in neurodegenerative diseases: implications for the clinical neurologist","volume":"101","author":"Alcolea","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0305","unstructured":"U.S. Food and Drug Administration. 510(k) Substantial equivalence determination decision summary: background information \u2013 a 510(k) number. Silver Spring (MD): Center for Devices and Radiological Health; [n.d.]."},{"key":"10.1016\/j.nrleng.2025.07.004_bib0310","unstructured":"U.S. Food and Drug Administration. Evaluation of automatic Class III designation for C-type test: fully automated, chemiluminescent enzyme immunoassays (CLEIA). Silver Spring (MD): Center for Devices and Radiological Health; [n.d.]."},{"key":"10.1016\/j.nrleng.2025.07.004_bib0315","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1474-4422(17)30159-X","article-title":"Strategic roadmap for an early diagnosis of Alzheimer\u2019s disease based on biomarkers","volume":"16","author":"Frisoni","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0320","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1007\/s00259-021-05253-y","article-title":"The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers","volume":"48","author":"Ashton","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0325","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","article-title":"Blood-based biomarkers for Alzheimer\u2019s disease: towards clinical implementation","volume":"21","author":"Teunissen","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0330","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3233\/JAD-221160","article-title":"Attitudes of neurologists toward the use of biomarkers in the diagnosis of early Alzheimer\u2019s disease","volume":"93","author":"Fortea","year":"2023","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0335","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/s43587-023-00471-5","article-title":"A two-step workflow based on plasma p-tau217 to screen for amyloid \u03b2 positivity with further confirmatory testing only in uncertain cases","volume":"3","author":"Brum","year":"2023","journal-title":"Nat Aging"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0340","doi-asserted-by":"crossref","first-page":"718","DOI":"10.14283\/jpad.2023.114","article-title":"Multimodal precision prevention \u2014 a new direction in Alzheimer\u2019s disease","volume":"10","author":"Barbera","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.nrleng.2025.07.004_bib0345","series-title":"Key barriers for clinical trials for Alzheimer\u2019s disease","author":"Malzbender","year":"2020"}],"container-title":["Neurolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173580825000665?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173580825000665?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T13:11:19Z","timestamp":1756732279000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173580825000665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":69,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2173580825000665"],"URL":"https:\/\/doi.org\/10.1016\/j.nrleng.2025.07.004","relation":{},"ISSN":["2173-5808"],"issn-type":[{"value":"2173-5808","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Blood-based biomarkers for Alzheimer's disease: positioning document and usage recommendations from the Behavioral Neurology and Dementia Study Group of the Spanish Society of Neurology","name":"articletitle","label":"Article Title"},{"value":"Neurolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nrleng.2025.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.nrl.2024.08.002","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Sociedad Espa\u00f1ola de Neurolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}